Written by Mary Marschner
Spoon Feed
In normotensive patients with type 2 diabetes and chronic kidney disease (CKD) with elevated cardiovascular risk (prior cardiovascular event or left ventricular hypertrophy), the addition of spironolactone prevented aortic plaque progression and reduced left ventricular mass or fibrosis seen on MRI at 12 months.
Synopsis
The MAGMA trial (Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis) demonstrated that daily spironolactone (25 mg) prevented aortic plaque progression and reduced left ventricular (LV) mass and fibrosis in patients with type 2 diabetes and CKD. Significant findings include a reduction in thoracic aortic wall volume progression (P = 0.022), a decrease in LV mass by 5.8 g (P = 0.001), and an improvement in myocardial fibrosis as evidenced by native T1 mapping (P < 0.001). These effects were largely independent of blood pressure changes, highlighting spironolactone’s anti-inflammatory and antifibrotic mechanisms, critical in mitigating cardiovascular risks in this population. (AI-generated)
Spironolactone, what a drug
This study is trying to tease out a mechanistic effect of mineralocorticoid antagonists on plaque formation and ventricular fibrosis beyond blood pressure. It examined the effects of spironolactone on a very specific population with normotension and high risk for cardiovascular complications: type 2 diabetes, CKD, and history of cardiovascular event or left ventricular hypertrophy. After 12 months, there was a statistically significant difference in aortic plaque and left ventricular fibrosis but not in blood pressure in patients on spironolactone. The limitation of the study is the small sample size and the short time frame of one year. For it to be clinically applicable, it would need to evaluate clinically significant events rather than using imaging findings as a surrogate. The study was valuable in suggesting the mechanism of spironolactone extends beyond blood pressure, perhaps to anti-plaque formation and anti-inflammatory effects. This study does not change my clinical practice, but it did expand my understanding of mineralocorticoid antagonists.
Source
Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial. Circulation. 2024 Aug 27;150(9):663-676. doi: 10.1161/CIRCULATIONAHA.123.067620. Epub 2024 Aug 12. PMID: 39129649
